DepoCyt was originally approved under an accelerated approval regulation, based on a preliminary demonstration of an increased complete response rate compared to the chemotherapy drug cytarabine. DepoCyt is
The development will add approximately 150,000 square feet in new laboratory, clinical development and office space to its existing facilities. Under the plan, Johnson & Johnson Pharmaceutical Research
The virus blocker may lead to new HIV treatments because it has a different mechanism of action. The research team found that fragments of a relatively abundant blood
The study achieved its primary objective, the absence of pain at two hours after dosing, with statistical significance, and also showed trends towards improvement in pain-free status and
Compared with placebo, Keppra was shown to significantly reduce the frequency of partial onset seizures in pediatric patients from one month to less than four years of age,
In the study, a 28-day treatment course of aztreonam lysine significantly improved the time to need for inhaled or intravenous antibiotics versus placebo. All patients received an initial
“The acquisition of a GLP and cGMP antigen relieves us of the expense of producing an antigen using our viral and cell banks. Thus, we can invest these
Alpharma said the agreement helped establish the company in the Chinese market and builds on a previous agreement with Zhejiang Hisun Pharmaceutical which it believes will double the
Zetia will help Schering-Plough to access the cholesterol-management market which is one of the largest worldwide, with total global sales of $34 billion according to IMS Health. In
The first study of the phase III program will assess an intermittent dosage regimen of cetrorelix as a potential safe and tolerable treatment providing prolonged improvement in benign
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.